Hims Launches Healthcare Super App, AI Drives Health Transformation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2026
0mins
Source: stocktwits
- AI Breakthrough: Hims CEO Andrew Dudum described Anthropic's latest AI advancement as transformative for population health, indicating a shift from 'super helpful' to 'superhuman', although HIMS shares dipped 1% ahead of Friday trading as investors weighed competition.
- Super App Strategy: Hims is building a comprehensive healthcare ecosystem, recently expanding its Hims & Hers Benefits platform by partnering with companies like iFIT and HelloFresh, which broadens its reach across fitness, nutrition, and women's health, aiming to enhance user experience and market competitiveness.
- AI Infrastructure: The newly launched Labs AI is termed as healthcare AI 'infrastructure', assisting users in understanding lab results and identifying long-term health risks through personalized analysis, marking a strategic shift in Hims' approach to integrating AI as a core component of healthcare services.
- International Expansion and Competition: Hims launched generic Semaglutide in Canada, marking its first international rollout, while strengthening ties with Novo Nordisk in the GLP-1 treatment space, despite aggressive competition from WeightWatchers and Eli Lilly in building their own healthcare ecosystems.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 26.820
Low
16.50
Averages
32.95
High
60.00
Current: 26.820
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HIMS Shares Eye Breakout Above $30 Resistance Level
- Price Fluctuation: HIMS shares peaked at $29.97 on Monday before dipping to $29.70, indicating market anticipation for a breakout above the $30 to $32 resistance level, which could propel the stock towards $40 if successful.
- Retail Sentiment Shift: Retail investor sentiment on Stocktwits shifted from neutral to bullish, with message volumes surging over 90%, reflecting optimistic expectations for HIMS's future performance and further driving the stock price upward.
- New Product Pre-Orders: CEO Andrew Dudum announced that the recently acquired Juniper platform is opening pre-orders for Novo Nordisk's Wegovy pill in the UK, marking a significant expansion into the weight loss drug market, which is expected to boost sales.
- Strategic Acquisition: HIMS completed the acquisition of digital health platform Eucalyptus, further expanding its presence in the U.S., UK, Australia, and Canada, with plans to achieve $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, demonstrating confidence in long-term growth.
See More
Mammoth Brands Takes on Traditional CPG Giants
- Significant Revenue Growth: Mammoth Brands anticipates reaching $835 million in revenue for 2024, with nearly $100 million in adjusted EBITDA, reflecting a robust compound annual growth rate exceeding 20%, indicating the success of its business model and increasing market acceptance.
- IPO Plans Emerging: The company is considering an initial public offering in the second half of 2024, aiming to attract a broader investor base and enhance its capital structure to support brand investments and market expansion, showcasing confidence in its future growth.
- Ongoing Acquisition Strategy: In 2025, Mammoth acquired the premium diaper brand Coterie for over $1 billion, with Coterie reporting over $200 million in net revenue over the past year, a nearly 60% increase, highlighting Mammoth's proactive approach to expanding its product lines and market share.
- Intensifying Market Competition: As smaller brands rise, traditional CPG giants face unprecedented challenges, with Mammoth redefining consumer expectations in personal care through its direct-to-consumer model and innovative products, driving industry transformation.
See More
Hims & Hers Health Faces Challenges and Opportunities
- Market Demand and Growth: Hims & Hers Health is striving to transform GLP-1 demand, subscriber growth, and international expansion into a larger healthcare platform, although it currently faces a sharp stock price decline and margin pressures, the long-term potential could still attract investor interest.
- Profitability Pressure: The company's current valuation remains demanding, and while the market holds an optimistic view on its future growth, short-term profitability may continue to be under pressure until it successfully cross-sells into higher-margin care categories.
- Investor Confidence Lacking: Despite the recognized potential of Hims & Hers Health in the healthcare sector, the Motley Fool Stock Advisor analyst team has not included it in their current list of best investment stocks, indicating a cautious market sentiment regarding its future performance.
- Historical Performance Comparison: Historically, companies like Netflix and Nvidia have shown outstanding performance when recommended, and if Hims & Hers Health can successfully transform, it may also achieve similar investment returns in the future.
See More
TD Cowen Raises Global GLP-1 Sales Forecast Significantly
- Market Share Forecast: TD Cowen projects that Eli Lilly (LLY) and Novo Nordisk (NVO) will maintain market leadership with expected shares of 62% and 31%, respectively, highlighting their strong competitive positions in the GLP-1 treatment sector.
- Sales Growth Outlook: The firm raised its global GLP-1 sales forecast to $150 billion by 2030, significantly above the previous estimate of $139 billion, with around 59 million patients expected to use GLP-1 therapies by the decade's end, indicating robust market demand.
- Oral Therapy Market Competition: Oral GLP-1 drugs are expected to account for 14% of overall sales, up from 11%, reflecting intensifying competition between Novo and Lilly in the oral weight-loss treatment market, with Novo's Wegovy pill gaining an early advantage.
- Stock Performance Comparison: While NVO shares have declined approximately 15% this year, LLY's stock has risen by 4%, indicating a bullish sentiment towards LLY, particularly in light of its rapid expansion in the oncology sector.
See More
Hims & Hers Aims to Expand Healthcare Platform Amid Challenges
- Market Demand Shift: Hims & Hers Health is attempting to transform GLP-1 drug demand into a larger healthcare platform, facing market pressures and valuation challenges, yet the long-term growth potential remains promising.
- User Growth Strategy: The company is focused on increasing subscriber numbers to drive revenue growth, and despite current stock price declines and margin pressures, successful cross-selling could enhance overall profitability.
- International Expansion Plans: Hims & Hers aims to expand its operations in international markets, intending to capture a broader customer base through globalization strategies, thereby enhancing market competitiveness.
- Profitability Challenges: While the potential for cross-selling in higher-margin care categories is significant, the current market valuation appears demanding, which may negatively impact short-term stock performance.
See More
Hims Launches Healthcare Super App, AI Drives Health Transformation
- AI Breakthrough: Hims CEO Andrew Dudum described Anthropic's latest AI advancement as transformative for population health, indicating a shift from 'super helpful' to 'superhuman', although HIMS shares dipped 1% ahead of Friday trading as investors weighed competition.
- Super App Strategy: Hims is building a comprehensive healthcare ecosystem, recently expanding its Hims & Hers Benefits platform by partnering with companies like iFIT and HelloFresh, which broadens its reach across fitness, nutrition, and women's health, aiming to enhance user experience and market competitiveness.
- AI Infrastructure: The newly launched Labs AI is termed as healthcare AI 'infrastructure', assisting users in understanding lab results and identifying long-term health risks through personalized analysis, marking a strategic shift in Hims' approach to integrating AI as a core component of healthcare services.
- International Expansion and Competition: Hims launched generic Semaglutide in Canada, marking its first international rollout, while strengthening ties with Novo Nordisk in the GLP-1 treatment space, despite aggressive competition from WeightWatchers and Eli Lilly in building their own healthcare ecosystems.
See More
HIMS Shares Eye Breakout Above $30 Resistance Level
- Price Fluctuation: HIMS shares peaked at $29.97 on Monday before dipping to $29.70, indicating market anticipation for a breakout above the $30 to $32 resistance level, which could propel the stock towards $40 if successful.
- Retail Sentiment Shift: Retail investor sentiment on Stocktwits shifted from neutral to bullish, with message volumes surging over 90%, reflecting optimistic expectations for HIMS's future performance and further driving the stock price upward.
- New Product Pre-Orders: CEO Andrew Dudum announced that the recently acquired Juniper platform is opening pre-orders for Novo Nordisk's Wegovy pill in the UK, marking a significant expansion into the weight loss drug market, which is expected to boost sales.
- Strategic Acquisition: HIMS completed the acquisition of digital health platform Eucalyptus, further expanding its presence in the U.S., UK, Australia, and Canada, with plans to achieve $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, demonstrating confidence in long-term growth.
See More
Mammoth Brands Takes on Traditional CPG Giants
- Significant Revenue Growth: Mammoth Brands anticipates reaching $835 million in revenue for 2024, with nearly $100 million in adjusted EBITDA, reflecting a robust compound annual growth rate exceeding 20%, indicating the success of its business model and increasing market acceptance.
- IPO Plans Emerging: The company is considering an initial public offering in the second half of 2024, aiming to attract a broader investor base and enhance its capital structure to support brand investments and market expansion, showcasing confidence in its future growth.
- Ongoing Acquisition Strategy: In 2025, Mammoth acquired the premium diaper brand Coterie for over $1 billion, with Coterie reporting over $200 million in net revenue over the past year, a nearly 60% increase, highlighting Mammoth's proactive approach to expanding its product lines and market share.
- Intensifying Market Competition: As smaller brands rise, traditional CPG giants face unprecedented challenges, with Mammoth redefining consumer expectations in personal care through its direct-to-consumer model and innovative products, driving industry transformation.
See More
Hims & Hers Health Faces Challenges and Opportunities
- Market Demand and Growth: Hims & Hers Health is striving to transform GLP-1 demand, subscriber growth, and international expansion into a larger healthcare platform, although it currently faces a sharp stock price decline and margin pressures, the long-term potential could still attract investor interest.
- Profitability Pressure: The company's current valuation remains demanding, and while the market holds an optimistic view on its future growth, short-term profitability may continue to be under pressure until it successfully cross-sells into higher-margin care categories.
- Investor Confidence Lacking: Despite the recognized potential of Hims & Hers Health in the healthcare sector, the Motley Fool Stock Advisor analyst team has not included it in their current list of best investment stocks, indicating a cautious market sentiment regarding its future performance.
- Historical Performance Comparison: Historically, companies like Netflix and Nvidia have shown outstanding performance when recommended, and if Hims & Hers Health can successfully transform, it may also achieve similar investment returns in the future.
See More
TD Cowen Raises Global GLP-1 Sales Forecast Significantly
- Market Share Forecast: TD Cowen projects that Eli Lilly (LLY) and Novo Nordisk (NVO) will maintain market leadership with expected shares of 62% and 31%, respectively, highlighting their strong competitive positions in the GLP-1 treatment sector.
- Sales Growth Outlook: The firm raised its global GLP-1 sales forecast to $150 billion by 2030, significantly above the previous estimate of $139 billion, with around 59 million patients expected to use GLP-1 therapies by the decade's end, indicating robust market demand.
- Oral Therapy Market Competition: Oral GLP-1 drugs are expected to account for 14% of overall sales, up from 11%, reflecting intensifying competition between Novo and Lilly in the oral weight-loss treatment market, with Novo's Wegovy pill gaining an early advantage.
- Stock Performance Comparison: While NVO shares have declined approximately 15% this year, LLY's stock has risen by 4%, indicating a bullish sentiment towards LLY, particularly in light of its rapid expansion in the oncology sector.
See More
Hims & Hers Aims to Expand Healthcare Platform Amid Challenges
- Market Demand Shift: Hims & Hers Health is attempting to transform GLP-1 drug demand into a larger healthcare platform, facing market pressures and valuation challenges, yet the long-term growth potential remains promising.
- User Growth Strategy: The company is focused on increasing subscriber numbers to drive revenue growth, and despite current stock price declines and margin pressures, successful cross-selling could enhance overall profitability.
- International Expansion Plans: Hims & Hers aims to expand its operations in international markets, intending to capture a broader customer base through globalization strategies, thereby enhancing market competitiveness.
- Profitability Challenges: While the potential for cross-selling in higher-margin care categories is significant, the current market valuation appears demanding, which may negatively impact short-term stock performance.
See More
Hims Launches Healthcare Super App, AI Drives Health Transformation
- AI Breakthrough: Hims CEO Andrew Dudum described Anthropic's latest AI advancement as transformative for population health, indicating a shift from 'super helpful' to 'superhuman', although HIMS shares dipped 1% ahead of Friday trading as investors weighed competition.
- Super App Strategy: Hims is building a comprehensive healthcare ecosystem, recently expanding its Hims & Hers Benefits platform by partnering with companies like iFIT and HelloFresh, which broadens its reach across fitness, nutrition, and women's health, aiming to enhance user experience and market competitiveness.
- AI Infrastructure: The newly launched Labs AI is termed as healthcare AI 'infrastructure', assisting users in understanding lab results and identifying long-term health risks through personalized analysis, marking a strategic shift in Hims' approach to integrating AI as a core component of healthcare services.
- International Expansion and Competition: Hims launched generic Semaglutide in Canada, marking its first international rollout, while strengthening ties with Novo Nordisk in the GLP-1 treatment space, despite aggressive competition from WeightWatchers and Eli Lilly in building their own healthcare ecosystems.
See More
